Tiziana Life Sciences has been granted a patent for a nanoparticle formulation of dactinomycin aimed at treating myelodysplastic syndrome (MDS) and NPM1-mutated acute myeloid leukemia (AML). The method involves administering a specific composition that achieves targeted therapeutic levels of dactinomycin. GlobalData’s report on Tiziana Life Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Tiziana Life Sciences, Cancer treatment biomarkers was a key innovation area identified from patents. Tiziana Life Sciences's grant share as of June 2024 was 17%. Grant share is based on the ratio of number of grants to total number of patents.
Nanoparticle formulation of dactinomycin for treating mds
The granted patent US11975111B2 outlines a novel method for treating myelodysplastic syndrome (MDS) through the administration of a composition that includes dactinomycin encapsulated in nanoparticles made from PLA-mPEG. The composition is designed to deliver a therapeutically effective amount of dactinomycin, with specific parameters including the encapsulating polymer comprising approximately 25% mPEG by weight and having a molecular weight of about 30,000 Da. The nanoparticles are characterized by an average size ranging from 100 nm to 200 nm, and the administration of this composition aims to achieve a peak plasma concentration (Cmax) of dactinomycin between 1 ng/mL and 20 ng/mL.
Additionally, the claims detail that the composition may include a surfactant, specifically polyvinyl alcohol, and can contain dactinomycin in a weight percentage of 5% to 15%. The method also allows for the inclusion of other chemotherapeutic agents, such as topoisomerase inhibitors, platinum-based therapies, anthracycline antibiotics, taxanes, tyrosine kinase inhibitors, nucleoside analogs, FLT3 inhibitors, and hypermethylation inhibitors. The patent specifies that these additional drugs can be included in various molar ratios relative to dactinomycin, ranging from 7:1 to less than 1:1, providing flexibility in treatment combinations for patients with MDS.
To know more about GlobalData’s detailed insights on Tiziana Life Sciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
